Senestech (NASDAQ:SNES – Get Free Report) and Zynex (NASDAQ:ZYXI – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.
Institutional & Insider Ownership
5.2% of Senestech shares are owned by institutional investors. Comparatively, 29.7% of Zynex shares are owned by institutional investors. 2.2% of Senestech shares are owned by insiders. Comparatively, 49.3% of Zynex shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Senestech and Zynex”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Senestech | $2.22 million | 3.20 | -$6.38 million | ($1.89) | -0.71 |
| Zynex | $108.20 million | 0.04 | $2.99 million | ($2.43) | -0.05 |
Zynex has higher revenue and earnings than Senestech. Senestech is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Senestech and Zynex’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Senestech | -304.22% | -67.60% | -49.21% |
| Zynex | -68.35% | -804.30% | -36.67% |
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Senestech and Zynex, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Senestech | 1 | 1 | 0 | 1 | 2.33 |
| Zynex | 1 | 1 | 1 | 0 | 2.00 |
Zynex has a consensus target price of $3.70, indicating a potential upside of 2,860.00%. Given Zynex’s higher probable upside, analysts plainly believe Zynex is more favorable than Senestech.
Volatility & Risk
Senestech has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500. Comparatively, Zynex has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500.
Summary
Zynex beats Senestech on 10 of the 15 factors compared between the two stocks.
About Senestech
SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. It offers ContraPest, a liquid bait that limits reproduction of male and female rats. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona.
About Zynex
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Receive News & Ratings for Senestech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senestech and related companies with MarketBeat.com's FREE daily email newsletter.
